<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587221</url>
  </required_header>
  <id_info>
    <org_study_id>V118_18</org_study_id>
    <secondary_id>2015-000728-27</secondary_id>
    <nct_id>NCT02587221</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age</brief_title>
  <official_title>A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate
      the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine
      Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2016</start_date>
  <completion_date type="Actual">July 23, 2018</completion_date>
  <primary_completion_date type="Actual">July 23, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on RT-PCR-confirmed Influenza Due to Any Strain Using Protocol Defined ILI Definition.</measure>
    <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
    <description>The primary efficacy endpoint was the time of first-occurrence of RT-PCR-confirmed influenza due to any strain of influenza regardless of antigenic match to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the primary endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Endpoint: The Percentage of Subjects in the Solicited Safety Subset With Solicited Local and Systemic Adverse Events (AE)</measure>
    <time_frame>Day 1 through Day 7</time_frame>
    <description>Safety of vaccination was assessed in terms of percentage of subjects reporting solicited local and systemic AEs up to 7 days after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Endpoint: Percentage of Subjects With Medically-attended Adverse Events (MAAEs)</measure>
    <time_frame>Within 30 days after of first occurrence RT-PCR confirmed Influenza</time_frame>
    <description>Safety of vaccination was assessed in terms of percentage of subjects reporting medically attended AEs within 30 days after of first occurrence RT-PCR confirmed influenza.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Endpoint: Percentages of Subjects With Any Unsolicited AE</measure>
    <time_frame>Day 1 through Day 366</time_frame>
    <description>Safety of vaccination was assessed in terms of percentage of subjects reporting unsolicited AEs up to 21 days after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Endpoint: Percentages of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), and Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Day 1 to Day 366</time_frame>
    <description>Safety of vaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, and AESIs up to 366 days after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on RT-PCR-confirmed Influenza Due to Any Strain Using Modified CDC ILI Definition.</measure>
    <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
    <description>The secondary efficacy endpoint was the time of first-occurrence of RT-PCR-confirmed influenza due to any strain of influenza regardless of antigenic match to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary efficacy endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Matched to the Strains Selected for the Seasonal Vaccine Using Protocol Defined ILI Definition.</measure>
    <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
    <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Matched to the Strains Selected for the Seasonal Vaccine Using Modified CDC ILI Definition.</measure>
    <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
    <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Regardless of Antigenic Match Using Protocol Defined ILI Definition.</measure>
    <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
    <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza regardless of antigenic match from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Regardless of Antigenic Match Using Modified CDC ILI Definition.</measure>
    <time_frame>Day 7 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
    <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza regardless of antigenic match from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Unmatched to the Strains Selected for the Seasonal Vaccine Using Protocol Defined ILI Definition.</measure>
    <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
    <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Unmatched to the Strains Selected for the Seasonal Vaccine Using Modified CDC ILI Definition.</measure>
    <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
    <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Geometric Mean Hemagglutination Inhibition (HI) Titers (GMT)</measure>
    <time_frame>Days 1 and 22</time_frame>
    <description>The log-transformed antibody titers (GMT) at Day 1 and Day 22 were evaluated using an analysis of covariance (ANCOVA) model including factors for site/country, pre-vaccination titer, age, and comorbidity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Geometric Mean Ratio (GMR) of Post-vaccination HI Titer Over the Pre-vaccination HI Titer</measure>
    <time_frame>Day 22/Day 1</time_frame>
    <description>The GMR was assessed as the postvaccination HI titer divided by the prevaccination HI titer (Day 22/Day 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Percentages of Subjects With an HI Titer ≥1:40</measure>
    <time_frame>Day 22</time_frame>
    <description>The percentage of subjects vaccinated with aQIV with a HI antibody titers ≥1:40 was assessed for each of the 4 strains Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% CI for percent of subjects with HI antibody titer ≥1:40 met or exceeded 60% at Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Percentages of Subjects Who Achieved Seroconversion (SCR)</measure>
    <time_frame>Day 22</time_frame>
    <description>The percentage of subjects achieving SCR at Day 22 was assessed for each of the 4 strains. SCR is defined as HI titer ≥1:40 for subjects seronegative at baseline (HI titer &lt;1:10) or a minimum 4-fold increase in HI titer for subjects seropositive at baseline (HI titer ≥1:10) on Day 22. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody SCR met or exceeded 30% at Day 22.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6790</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>aQIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MF59-adjuvanted Quadrivalent Influenza Vaccine (aQIV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-influenza Comparator Vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-influenza comparator vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)</intervention_name>
    <description>1 dose approximately 0.5 mL of aQIV</description>
    <arm_group_label>aQIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-Influenza Comparator (Boostrix)</intervention_name>
    <description>1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine (Boostrix)</description>
    <arm_group_label>Non-influenza Comparator Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females ≥ 65 years old who are healthy or have co-morbidities

          2. Individuals who or whose legal guardian have voluntarily given written consent after
             the nature of the study has been explained according to local regulatory requirements,
             prior to study entry.

          3. Ability to attend all scheduled visits and to comply with study procedures

        Exclusion Criteria:

          1. Hypersensitivity, including allergy to any component of vaccines foreseen in this
             study

          2. Abnormal function of the immune system.

          3. Receipt of any influenza vaccine within 6 months prior to enrolment in this study or
             who plan to receive influenza vaccine while participating in the study.

          4. Additional eligibility criteria may be discussed by contacting the site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Program Manager</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MHAT St. Ekaterina</name>
      <address>
        <city>Dimitrovgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Sv Nikolay Chudotvoretz Lom</name>
      <address>
        <city>Lom</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL TRIMONCIUM (Synexus)</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATPPD-Ruse</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mhat Silistra</name>
      <address>
        <city>Silistra</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mc Smolyan</name>
      <address>
        <city>Smolyan</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mc Avicena Sofia</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Excelsior</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical center Synexus Sofia EOOD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATPPD-Sofia, City</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre Orpheus OOD (Synexus)</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Medellín-Luz Castro de Gutiérrez - E.S.E</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <zip>0500515</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caja de Compesanción Familiar CAFAM</name>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <zip>74136-3367</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardiomet CEQUIN - Internal Medicine</name>
      <address>
        <city>Armenia</city>
        <zip>NAP</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa</name>
      <address>
        <city>Barranquilla</city>
        <zip>NAP</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Atención e Investigación Médica S.A.S. - CAIMED S.A.S.</name>
      <address>
        <city>Bogotá</city>
        <zip>NAP</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medplus Medicina Prepagada</name>
      <address>
        <city>Bogotá</city>
        <zip>NAP</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asociacion IPS Medicos Internistas de Caldas</name>
      <address>
        <city>Manizales</city>
        <zip>170004</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Czech Brno, s.r.o.</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum ockovani a cestovni mediciny</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Ostrava, s.r.o.</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Czech, a.s.</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical and Basic Research</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicum AS</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merelahe Family Doctors Centre</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vee Family Doctors Centre</name>
      <address>
        <city>Paide</city>
        <state>Järvamaa</state>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Doctors Pullerits &amp; Gavronski</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr Liga Kozlovska</name>
      <address>
        <city>Balvi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr Ruta Eglite</name>
      <address>
        <city>Kuldiga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Doctor Andra Lasmane clinic &quot;ALMA&quot;</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr Inese Petrova</name>
      <address>
        <city>Tukums</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC Saules seimos medicinos centras</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kauno klinikine ligonine</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lietuvos Sveikatos Mokslų Universitetas</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UAB InMedica</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Siauliai Hospital</name>
      <address>
        <city>Siauliai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Bahiyah</name>
      <address>
        <city>Alor Setar</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Selayang</name>
      <address>
        <city>Batu Caves</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Greentown</name>
      <address>
        <city>Ipoh</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Raja Perempuan Zainab II</name>
      <address>
        <city>Kota Bharu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre (UMMC)</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Seremban 2</name>
      <address>
        <city>Seremban</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Seri Manjung</name>
      <address>
        <city>Seri Manjung</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sibu</name>
      <address>
        <city>Sibu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De La Salle Health Sciences Institute</name>
      <address>
        <city>Dasmariñas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Visayas State University - Medical Center</name>
      <address>
        <city>Jaro</city>
        <state>Iloilo</state>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quirino Memorial Medical Center</name>
      <address>
        <city>Quezon</city>
        <state>National Capital Region</state>
        <zip>1109</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marilao St. Michael Family Hospital</name>
      <address>
        <city>Bulacan</city>
        <zip>3019</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan De Dios Hospital</name>
      <address>
        <city>Pasay</city>
        <zip>1300</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o.</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej VITAMED</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne &quot;OMEGA&quot; sp. z o.o.</name>
      <address>
        <city>Plock</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Warszawa</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Osrodek Medycyny Wieku Dojrzalego</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Gdynia</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Katowice</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praktyka Lekarzy Rodzinnych SALUS</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PRATIA Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Osrodek Medycyny Wieku Dojrzalego sp. z o.o.</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMed Oddział Nowy Duninow</name>
      <address>
        <city>Nowy Duninow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMed Oddzial Sochaczew</name>
      <address>
        <city>Sochaczew</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Trials Institute</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet dr. Dana OLAR</name>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical de Diagnostic si Tratament Ambulator NEOMED</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical Individual Craciun-Nicodin Maria Marcela</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Sana</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medicala Synexus</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic C.F. Cluj-Napoca</name>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintrial Medical Center</name>
      <address>
        <city>Resca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundatia Cardioprevent</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahidol University (MU) - Faculty of Tropical Medicine</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen University - Srinagarind Hospital - Medicine</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Diseases Institute (BIDI)</name>
      <address>
        <city>Mueang Nonthaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Medical Faculty</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty</name>
      <address>
        <city>Cerrahpaşa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ataturk University Medical Faculty</name>
      <address>
        <city>Erzurum</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kocaeli University Research and Application Hospital</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakarya Training and Research Hospital</name>
      <address>
        <city>Sakarya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Thailand</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <results_first_submitted>March 19, 2020</results_first_submitted>
  <results_first_submitted_qc>May 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2020</results_first_posted>
  <disposition_first_submitted>November 24, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>December 30, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 2, 2019</disposition_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02587221/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02587221/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study enrolled male and female adults ≥ 65 years old who were healthy or had co-morbidities.</recruitment_details>
      <pre_assignment_details>Screening criteria applied.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>aQIV</title>
          <description>A single dose of approximately 0.5 mL of aQIV was administered on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Non-influenza Comparator Vaccine</title>
          <description>A single dose of approximately 0.5 mL dose of Boostrix was administered on Day 1. (Boostrix = Non-influenza comparator vaccine)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3394"/>
                <participants group_id="P2" count="3396"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="3379"/>
                <participants group_id="P2" count="3382"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3263"/>
                <participants group_id="P2" count="3273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason or Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total Number of Subjects Enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>aQIV</title>
          <description>Subjects received one dose of aQIV vaccine</description>
        </group>
        <group group_id="B2">
          <title>Non-influenza Comparator Vaccine</title>
          <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3394"/>
            <count group_id="B2" value="3396"/>
            <count group_id="B3" value="6790"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.9" spread="5.53"/>
                    <measurement group_id="B2" value="71.8" spread="5.36"/>
                    <measurement group_id="B3" value="71.9" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>65 to 74 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2416"/>
                    <measurement group_id="B2" value="2406"/>
                    <measurement group_id="B3" value="4822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 to 84 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="893"/>
                    <measurement group_id="B2" value="928"/>
                    <measurement group_id="B3" value="1821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>. 85 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2105"/>
                    <measurement group_id="B2" value="2089"/>
                    <measurement group_id="B3" value="4194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1289"/>
                    <measurement group_id="B2" value="1307"/>
                    <measurement group_id="B3" value="2596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="615"/>
                    <measurement group_id="B2" value="607"/>
                    <measurement group_id="B3" value="1222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2773"/>
                    <measurement group_id="B2" value="2779"/>
                    <measurement group_id="B3" value="5552"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1139"/>
                    <measurement group_id="B2" value="1159"/>
                    <measurement group_id="B3" value="2298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1642"/>
                    <measurement group_id="B2" value="1629"/>
                    <measurement group_id="B3" value="3271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="550"/>
                    <measurement group_id="B2" value="549"/>
                    <measurement group_id="B3" value="1099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bulgaria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="613"/>
                    <measurement group_id="B2" value="611"/>
                    <measurement group_id="B3" value="1224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="324"/>
                    <measurement group_id="B2" value="317"/>
                    <measurement group_id="B3" value="641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="446"/>
                    <measurement group_id="B2" value="453"/>
                    <measurement group_id="B3" value="899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="453"/>
                    <measurement group_id="B2" value="457"/>
                    <measurement group_id="B3" value="910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="361"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="248"/>
                    <measurement group_id="B3" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <population>According to data availability.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3391"/>
                    <count group_id="B2" value="3393"/>
                    <count group_id="B3" value="6784"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.05" spread="4.989"/>
                    <measurement group_id="B2" value="26.96" spread="4.995"/>
                    <measurement group_id="B3" value="27.00" spread="4.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Seasonal Influenza Vaccine in the Past 5 Years</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="991"/>
                    <measurement group_id="B2" value="1021"/>
                    <measurement group_id="B3" value="2012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2403"/>
                    <measurement group_id="B2" value="2375"/>
                    <measurement group_id="B3" value="4778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidity Score</title>
          <description>Comorbidity risk scores were assessed among other baseline characteristics as a validated predictor of risk of influenza complications in subjects ≥65 years of age using a model-based approach assessing 5 disease classifications (pulmonary disease, heart disease, renal disease, dementia or stroke, and non-hematological and hematological cancer [excluding cancer of the skin other than melanoma]). Using this model, a score of &lt;50 was considered low risk and a score of ≥50 was considered high risk for hospitalization due to pneumonia or influenza and death from any cause.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2472"/>
                    <measurement group_id="B2" value="2474"/>
                    <measurement group_id="B3" value="4946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="922"/>
                    <measurement group_id="B2" value="922"/>
                    <measurement group_id="B3" value="1844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Smoking</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="335"/>
                    <measurement group_id="B3" value="660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not smoking</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3394"/>
                    <count group_id="B2" value="3396"/>
                    <count group_id="B3" value="6790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3069"/>
                    <measurement group_id="B2" value="3061"/>
                    <measurement group_id="B3" value="6130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on RT-PCR-confirmed Influenza Due to Any Strain Using Protocol Defined ILI Definition.</title>
        <description>The primary efficacy endpoint was the time of first-occurrence of RT-PCR-confirmed influenza due to any strain of influenza regardless of antigenic match to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the primary endpoint.</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on RT-PCR-confirmed Influenza Due to Any Strain Using Protocol Defined ILI Definition.</title>
          <description>The primary efficacy endpoint was the time of first-occurrence of RT-PCR-confirmed influenza due to any strain of influenza regardless of antigenic match to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the primary endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The efficacy of aQIV would be demonstrated if the LL of the two-sided multiplicity adjusted 95%CI for the vaccine efficacy is &gt;40%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of RT-PCR confirmed due to any strain.
An ILI was defined as presence of ≥1 respiratory symptom (e.g. sore throat, cough, sputum production, wheezing, or difficulty breathing) concurrently with ≥1 systemic symptom (temp &gt;37.2°C/99°F, chills, tiredness, headache, or myalgia) (protocol defined ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>19.80</param_value>
            <ci_percent>97.45</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.27</ci_lower_limit>
            <ci_upper_limit>38.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Endpoint: The Percentage of Subjects in the Solicited Safety Subset With Solicited Local and Systemic Adverse Events (AE)</title>
        <description>Safety of vaccination was assessed in terms of percentage of subjects reporting solicited local and systemic AEs up to 7 days after vaccination.</description>
        <time_frame>Day 1 through Day 7</time_frame>
        <population>SOLICITED SAFETY SET = randomly selected subset of all treated subjects, with solicited safety assessments beyond 30 minutes</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: The Percentage of Subjects in the Solicited Safety Subset With Solicited Local and Systemic Adverse Events (AE)</title>
          <description>Safety of vaccination was assessed in terms of percentage of subjects reporting solicited local and systemic AEs up to 7 days after vaccination.</description>
          <population>SOLICITED SAFETY SET = randomly selected subset of all treated subjects, with solicited safety assessments beyond 30 minutes</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
                <count group_id="O2" value="667"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3"/>
                    <measurement group_id="O2" value="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Endpoint: Percentage of Subjects With Medically-attended Adverse Events (MAAEs)</title>
        <description>Safety of vaccination was assessed in terms of percentage of subjects reporting medically attended AEs within 30 days after of first occurrence RT-PCR confirmed influenza.</description>
        <time_frame>Within 30 days after of first occurrence RT-PCR confirmed Influenza</time_frame>
        <population>UNSOLICITED SAFETY SET - consisting of treated subjects with unsolicited AE data was used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Percentage of Subjects With Medically-attended Adverse Events (MAAEs)</title>
          <description>Safety of vaccination was assessed in terms of percentage of subjects reporting medically attended AEs within 30 days after of first occurrence RT-PCR confirmed influenza.</description>
          <population>UNSOLICITED SAFETY SET - consisting of treated subjects with unsolicited AE data was used for analysis.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Endpoint: Percentages of Subjects With Any Unsolicited AE</title>
        <description>Safety of vaccination was assessed in terms of percentage of subjects reporting unsolicited AEs up to 21 days after vaccination.</description>
        <time_frame>Day 1 through Day 366</time_frame>
        <population>UNSOLICITED SAFETY SET - treated subjects with unsolicited AE data was used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Percentages of Subjects With Any Unsolicited AE</title>
          <description>Safety of vaccination was assessed in terms of percentage of subjects reporting unsolicited AEs up to 21 days after vaccination.</description>
          <population>UNSOLICITED SAFETY SET - treated subjects with unsolicited AE data was used for analysis.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3380"/>
                <count group_id="O2" value="3377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Endpoint: Percentages of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), and Adverse Events of Special Interest (AESI)</title>
        <description>Safety of vaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, and AESIs up to 366 days after vaccination.</description>
        <time_frame>Day 1 to Day 366</time_frame>
        <population>UNSOLICITED SAFETY SET - treated subjects with unsolicited AE data was used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Percentages of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), and Adverse Events of Special Interest (AESI)</title>
          <description>Safety of vaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, and AESIs up to 366 days after vaccination.</description>
          <population>UNSOLICITED SAFETY SET - treated subjects with unsolicited AE data was used for analysis.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3380"/>
                <count group_id="O2" value="3377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any unsolicited SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any unsolicited AEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any NOCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on RT-PCR-confirmed Influenza Due to Any Strain Using Modified CDC ILI Definition.</title>
        <description>The secondary efficacy endpoint was the time of first-occurrence of RT-PCR-confirmed influenza due to any strain of influenza regardless of antigenic match to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary efficacy endpoint.</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on RT-PCR-confirmed Influenza Due to Any Strain Using Modified CDC ILI Definition.</title>
          <description>The secondary efficacy endpoint was the time of first-occurrence of RT-PCR-confirmed influenza due to any strain of influenza regardless of antigenic match to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary efficacy endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of RT-PCR confirmed due to any strain.
An ILI was defined as the presence of fever (temperature &gt;37.2°C) with cough or sore throat (modified CDC ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>32.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.23</ci_lower_limit>
            <ci_upper_limit>48.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Matched to the Strains Selected for the Seasonal Vaccine Using Protocol Defined ILI Definition.</title>
        <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Matched to the Strains Selected for the Seasonal Vaccine Using Protocol Defined ILI Definition.</title>
          <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The efficacy of aQIV would be demonstrated if the LL of the two-sided multiplicity adjusted 95%CI for the vaccine efficacy is &gt;40%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the vaccine strains.
An ILI was defined as the presence of ≥1 respiratory symptom (eg. sore throat, cough, sputum production, wheezing, or difficulty breathing) concurrently with ≥1 systemic symptom (temp &gt;37.2°C/99°F, chills, tiredness, headache, or myalgia) (protocol defined ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>49.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.03</ci_lower_limit>
            <ci_upper_limit>79.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Matched to the Strains Selected for the Seasonal Vaccine Using Modified CDC ILI Definition.</title>
        <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Matched to the Strains Selected for the Seasonal Vaccine Using Modified CDC ILI Definition.</title>
          <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the strains selected for the seasonal vaccine.
An ILI was defined as presence of fever (temperature &gt;37.2°C) with cough or sore throat (modified CDC ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>61.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.98</ci_lower_limit>
            <ci_upper_limit>86.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Regardless of Antigenic Match Using Protocol Defined ILI Definition.</title>
        <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza regardless of antigenic match from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Regardless of Antigenic Match Using Protocol Defined ILI Definition.</title>
          <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza regardless of antigenic match from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of culture confirmed influenza due to any vaccine strain regardless of antigenic match.
An ILI was defined as the presence of ≥1 respiratory symptom (e.g. sore throat, cough, sputum production, wheezing, or difficulty breathing) concurrently with ≥1 systemic symptom (temp &gt;37.2°C/99°F, chills, tiredness, headache, or myalgia) (protocol defined ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>28.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>49.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Regardless of Antigenic Match Using Modified CDC ILI Definition.</title>
        <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza regardless of antigenic match from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
        <time_frame>Day 7 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Regardless of Antigenic Match Using Modified CDC ILI Definition.</title>
          <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza regardless of antigenic match from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of culture confirmed influenza due to any strain of influenza regardless of antigenic match
An ILI was defined as presence of fever (temperature &gt;37.2°C) with cough or sore throat (modified CDC ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>33.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.56</ci_lower_limit>
            <ci_upper_limit>54.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Unmatched to the Strains Selected for the Seasonal Vaccine Using Protocol Defined ILI Definition.</title>
        <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Unmatched to the Strains Selected for the Seasonal Vaccine Using Protocol Defined ILI Definition.</title>
          <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using protocol defined ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the vaccine strains.
An ILI is the presence of ≥1 respiratory symptom (e.g. sore throat, cough, sputum production, wheezing, or difficulty breathing) concurrently with ≥1 systemic symptom (temp &gt;37.2°C/99°F, chills, tiredness, headache, or myalgia) (protocol defined ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>23.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.69</ci_lower_limit>
            <ci_upper_limit>47.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Unmatched to the Strains Selected for the Seasonal Vaccine Using Modified CDC ILI Definition.</title>
        <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Unmatched to the Strains Selected for the Seasonal Vaccine Using Modified CDC ILI Definition.</title>
          <description>The secondary efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using modified CDC ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the secondary endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the strains selected for the seasonal vaccine.
An ILI was defined as presence of fever (temperature &gt;37.2°C) with cough or sore throat (modified CDC ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>26.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.71</ci_lower_limit>
            <ci_upper_limit>51.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Geometric Mean Hemagglutination Inhibition (HI) Titers (GMT)</title>
        <description>The log-transformed antibody titers (GMT) at Day 1 and Day 22 were evaluated using an analysis of covariance (ANCOVA) model including factors for site/country, pre-vaccination titer, age, and comorbidity.</description>
        <time_frame>Days 1 and 22</time_frame>
        <population>The FAS Immunogenicity, consisting of all randomized subjects who received a study treatment, and provided immunogenicity data at Days 1 and 22, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Geometric Mean Hemagglutination Inhibition (HI) Titers (GMT)</title>
          <description>The log-transformed antibody titers (GMT) at Day 1 and Day 22 were evaluated using an analysis of covariance (ANCOVA) model including factors for site/country, pre-vaccination titer, age, and comorbidity.</description>
          <population>The FAS Immunogenicity, consisting of all randomized subjects who received a study treatment, and provided immunogenicity data at Days 1 and 22, was used for analysis</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1324"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.86" lower_limit="28.49" upper_limit="35.63"/>
                    <measurement group_id="O2" value="36.19" lower_limit="30.05" upper_limit="43.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438.79" lower_limit="403.82" upper_limit="476.79"/>
                    <measurement group_id="O2" value="29.43" lower_limit="25.63" upper_limit="33.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.31" lower_limit="25.43" upper_limit="31.52"/>
                    <measurement group_id="O2" value="27.56" lower_limit="23.05" upper_limit="32.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="572.80" lower_limit="525.08" upper_limit="624.86"/>
                    <measurement group_id="O2" value="27.06" lower_limit="23.42" upper_limit="31.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.83" lower_limit="12.81" upper_limit="14.92"/>
                    <measurement group_id="O2" value="13.13" lower_limit="11.57" upper_limit="14.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.77" lower_limit="79.94" upper_limit="94.19"/>
                    <measurement group_id="O2" value="12.49" lower_limit="10.90" upper_limit="14.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.77" lower_limit="11.81" upper_limit="13.81"/>
                    <measurement group_id="O2" value="12.26" lower_limit="10.77" upper_limit="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.26" lower_limit="95.77" upper_limit="113.50"/>
                    <measurement group_id="O2" value="11.25" lower_limit="9.77" upper_limit="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Geometric Mean Ratio (GMR) of Post-vaccination HI Titer Over the Pre-vaccination HI Titer</title>
        <description>The GMR was assessed as the postvaccination HI titer divided by the prevaccination HI titer (Day 22/Day 1).</description>
        <time_frame>Day 22/Day 1</time_frame>
        <population>The FAS Immunogenicity, consisting of all randomized subjects who received a study treatment, and provided immunogenicity data at Days 1 and 22, was used for analysis GMR B/Vic: 0.94 to )</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Geometric Mean Ratio (GMR) of Post-vaccination HI Titer Over the Pre-vaccination HI Titer</title>
          <description>The GMR was assessed as the postvaccination HI titer divided by the prevaccination HI titer (Day 22/Day 1).</description>
          <population>The FAS Immunogenicity, consisting of all randomized subjects who received a study treatment, and provided immunogenicity data at Days 1 and 22, was used for analysis GMR B/Vic: 0.94 to )</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1324"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.17" lower_limit="12.84" upper_limit="15.64"/>
                    <measurement group_id="O2" value="0.89" lower_limit="0.76" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.65" lower_limit="20.48" upper_limit="25.06"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.92" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.58" lower_limit="6.02" upper_limit="7.20"/>
                    <measurement group_id="O2" value="0.97" lower_limit="0.84" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" lower_limit="7.83" upper_limit="9.42"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.81" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Percentages of Subjects With an HI Titer ≥1:40</title>
        <description>The percentage of subjects vaccinated with aQIV with a HI antibody titers ≥1:40 was assessed for each of the 4 strains Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% CI for percent of subjects with HI antibody titer ≥1:40 met or exceeded 60% at Day 22.</description>
        <time_frame>Day 22</time_frame>
        <population>The FAS Immunogenicity, consisting of all randomized subjects who received a study treatment, and provided immunogenicity data at Days 1 and 22, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Percentages of Subjects With an HI Titer ≥1:40</title>
          <description>The percentage of subjects vaccinated with aQIV with a HI antibody titers ≥1:40 was assessed for each of the 4 strains Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% CI for percent of subjects with HI antibody titer ≥1:40 met or exceeded 60% at Day 22.</description>
          <population>The FAS Immunogenicity, consisting of all randomized subjects who received a study treatment, and provided immunogenicity data at Days 1 and 22, was used for analysis</population>
          <units>Percentage of subjects</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1324"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="95.05" upper_limit="97.18"/>
                    <measurement group_id="O2" value="46.7" lower_limit="41.18" upper_limit="52.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="94.37" upper_limit="96.66"/>
                    <measurement group_id="O2" value="41.7" lower_limit="36.32" upper_limit="47.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="76.95" upper_limit="81.40"/>
                    <measurement group_id="O2" value="21.5" lower_limit="17.20" upper_limit="26.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" lower_limit="79.39" upper_limit="83.65"/>
                    <measurement group_id="O2" value="18.4" lower_limit="14.40" upper_limit="23.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Percentages of Subjects Who Achieved Seroconversion (SCR)</title>
        <description>The percentage of subjects achieving SCR at Day 22 was assessed for each of the 4 strains. SCR is defined as HI titer ≥1:40 for subjects seronegative at baseline (HI titer &lt;1:10) or a minimum 4-fold increase in HI titer for subjects seropositive at baseline (HI titer ≥1:10) on Day 22. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody SCR met or exceeded 30% at Day 22.</description>
        <time_frame>Day 22</time_frame>
        <population>analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Percentages of Subjects Who Achieved Seroconversion (SCR)</title>
          <description>The percentage of subjects achieving SCR at Day 22 was assessed for each of the 4 strains. SCR is defined as HI titer ≥1:40 for subjects seronegative at baseline (HI titer &lt;1:10) or a minimum 4-fold increase in HI titer for subjects seropositive at baseline (HI titer ≥1:10) on Day 22. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody SCR met or exceeded 30% at Day 22.</description>
          <population>analysis.</population>
          <units>Percentage of subjects</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1324"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="75.66" upper_limit="80.21"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.85" upper_limit="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" lower_limit="82.52" upper_limit="86.49"/>
                    <measurement group_id="O2" value="3.9" lower_limit="2.11" upper_limit="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="58.06" upper_limit="63.41"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.89" upper_limit="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" lower_limit="62.88" upper_limit="68.10"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.85" upper_limit="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on RT-PCR-confirmed Influenza Due to Any Strain Using WHO ILI Definition.</title>
        <description>The post-hoc efficacy endpoint was the time of first-occurrence of RT-PCR-confirmed influenza due to any strain of influenza regardless of antigenic match to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using WHO ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the post-hoc efficacy endpoint</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on RT-PCR-confirmed Influenza Due to Any Strain Using WHO ILI Definition.</title>
          <description>The post-hoc efficacy endpoint was the time of first-occurrence of RT-PCR-confirmed influenza due to any strain of influenza regardless of antigenic match to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using WHO ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the post-hoc efficacy endpoint</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of RT-PCR confirmed due to any strain.
An ILI was defined as presence of fever (temperature ≥38°C) with cough (WHO ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>51.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>28.21</ci_lower_limit>
            <ci_upper_limit>66.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Matched to the Strains Selected for the Seasonal Vaccine Using WHO ILI Definition.</title>
        <description>The post-hoc efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using WHO ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the post-hoc endpoint.</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Matched to the Strains Selected for the Seasonal Vaccine Using WHO ILI Definition.</title>
          <description>The post-hoc efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using WHO ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the post-hoc endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of culture confirmed influenza due to any strain of influenza antigenically matched to the strains selected for the seasonal vaccine.
An ILI was defined as presence of fever (temperature ≥38°C) with cough (WHO ILI definition)</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>74.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.93</ci_lower_limit>
            <ci_upper_limit>94.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Regardless of Antigenic Match Using WHO ILI Definition</title>
        <description>The post-hoc efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza regardless of antigenic match from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using WHO ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the post-hoc endpoint.</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Regardless of Antigenic Match Using WHO ILI Definition</title>
          <description>The post-hoc efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza regardless of antigenic match from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using WHO ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the post-hoc endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of culture confirmed influenza due to any strain of influenza regardless of antigenic match.
An ILI was defined as presence of fever (temperature ≥38°C) with cough (WHO ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>60.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.19</ci_lower_limit>
            <ci_upper_limit>76.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Unmatched to the Strains Selected for the Seasonal Vaccine Using WHO ILI Definition.</title>
        <description>The post-hoc efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using WHO ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the post-hoc endpoint.</description>
        <time_frame>Day 21 to Day 180 after vaccination or end of influenza season, whichever is longer</time_frame>
        <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>Subjects received one dose of aQIV vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-influenza Comparator Vaccine</title>
            <description>Subjects received one dose of non-influenza comparator vaccine (Boostrix)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on Culture Confirmed Influenza Due to Any Strain of Influenza Antigenically Unmatched to the Strains Selected for the Seasonal Vaccine Using WHO ILI Definition.</title>
          <description>The post-hoc efficacy endpoint was the time of first-occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the strains selected for the seasonal vaccine from Day 21 through 180 days after vaccination or end of the influenza season, whichever is longer, using WHO ILI definition. Absolute vaccine efficacy is VE=1-HR, where HR is the hazard ratio of aQIV vs non-influenza comparator estimated by the Cox proportional hazards model for the post-hoc endpoint.</description>
          <population>The Full Analysis Set (FAS) Efficacy, consisting of all randomized subjects who received a study treatment, were under observation for at least 21 days post-vaccination and provided efficacy data, was used for analysis</population>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="3372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>VE=1-HR, where HR is the hazard ratio estimated by the Cox proportional hazards model for time to first occurrence of culture confirmed influenza due to any strain of influenza antigenically unmatched to the strains selected for the seasonal vaccine.
An ILI was defined as presence of fever (temperature ≥38°C) with cough (WHO ILI definition).</non_inferiority_desc>
            <param_type>Vaccine efficacy (VE)</param_type>
            <param_value>57.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.73</ci_lower_limit>
            <ci_upper_limit>76.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs: Day 1 to Day 7; SAEs: Day 1 to Day 366; and Unsolicited AEs: Day 1 to Day 22.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>aQIV</title>
          <description>A single dose of approximately 0.5 mL of aQIV was administered on Day 1 (NH 2016/17, SH 2017).</description>
        </group>
        <group group_id="E2">
          <title>Non-influenza Comparator Vaccine</title>
          <description>Non-influenza Comparator Vaccine / A single dose of approximately 0.5 mL dose of Boostrix was administered on Day 1 (NH 2016/17, SH 2017). (Boostrix = Non-influenza comparator vaccine)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="238" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cor pulmonale acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Polypoidal choroidal vasculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hepatitis chronic persistent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Infection parasitic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Nasal vestibulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Parasitic gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Parotid abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Splenic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Subarachnoid haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Tracheostomy malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Carbohydrate antigen 19-9 increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Fracture delayed union</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Gallbladder adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Head and neck cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Penile cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Cerebrovascular stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Vertigo CNS origin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Vocal cord paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Delusional disorder, unspecified type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hypertensive nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Urethral polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Pemphigus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Aortic dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3380"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3377"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="665"/>
                <counts group_id="E2" subjects_affected="218" subjects_at_risk="667"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any formal publication of the study in which contribution of Seqirus personnel exceeded that of conventional monitoring will be considered as a joint publication by the investigator and the appropriate Seqirus personnel. Seqirus must be notified of any intent to publish data collected from the study and prior approval from Seqirus must be obtained prior to submission for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Seqirus Clinical Trial Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <phone>1-855-358-8966</phone>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

